Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.65 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.65 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.42 |
| ▸ | CTSS | P25774 | 1/20 | 0.41 |
| ▸ | CTSK | P43235 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | CXCR6 | O00574 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1851171 | 0.83 | KMT2A (0.91) | KMT2AL3MBTL1MEN1OPRK1ALDH1A1 | |
| SCHEMBL29725667 | 0.82 | KMT2A (0.73) | KMT2AL3MBTL1MEN1OPRK1USP2 | |
| SCHEMBL30201430 | 0.82 | KMT2A (0.73) | KMT2AL3MBTL1MEN1OPRK1USP2 | |
| SCHEMBL4855029 | 0.81 | KMT2A (0.71) | KMT2AL3MBTL1MEN1OPRK1 | |
| SCHEMBL4794886 | 0.79 | L3MBTL1 (1.00) | KMT2AL3MBTL1OPRK1ALDH1A1CYP2D6 | |
| SCHEMBL29410965 | 0.79 | L3MBTL1 (1.00) | KMT2AL3MBTL1OPRK1ALDH1A1CYP2D6 | |
| SCHEMBL20967988 | 0.79 | L3MBTL1 (1.00) | KMT2AL3MBTL1OPRK1ALDH1A1CYP2D6 | |
| SCHEMBL29725634 | 0.78 | KMT2A (0.72) | KMT2AL3MBTL1MEN1OPRK1USP2 | |
| SCHEMBL2612633 | 0.75 | KMT2A (0.66) | KMT2AL3MBTL1MEN1OPRK1USP2 | |
| SCHEMBL2096601 | 0.75 | KMT2A (0.66) | KMT2AL3MBTL1MEN1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7456192-B2 | 3β-amino azabicyclooctane heteroaromatic amid derivatives preparation method and therapeutic uses thereof | PIERRE FABRE MEDICAMENT (FR) | 2008-11-25 | — | — | US | disclosed |
| EP-1440075-B1 | NOVEL 3BETA-AMINO AZABICYCLOOCTANE HETEROAROMATIC AMIDE DERIVATIVES, PREPARATION METHOD AND THERAPEUTIC USES THEREOF | PF MEDICAMENT (FR) | 2005-06-08 | — | — | EP | disclosed |
| US-20050080085-A1 | Novel 3beta-amino azabicyclooctane heteroaromatic amid derivatives preparation method and therapeutic uses thereof | PIERRE FABRE MEDICAMENT (FR) | 2005-04-14 | — | — | US | disclosed |
| EP-1440075-A1 | NOVEL 3BETA-AMINO AZABICYCLOOCTANE HETEROAROMATIC AMIDE DERIVATIVES, PREPARATION METHOD AND THERAPEUTIC USES THEREOF | PIERRE FABRE MEDICAMENT (FR) | 2004-07-28 | — | — | EP | disclosed |
| WO-2003037904-A1 | NOVEL 3BETA-AMINO AZABICYCLOOCTANE HETEROAROMATIC AMIDE DERIVATIVES, PREPARATION METHOD AND THERAPEUTIC USES THEREOF | PIERRE FABRE MEDICAMENT (FR) | 2003-05-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050080085-A1 | Novel 3beta-amino azabicyclooctane heteroaromatic amid derivatives preparation method and therapeutic uses thereof | AOC3, MAOB, AOC1 | KMT2A 2929/4885L3MBTL1 2042/4885MEN1 1642/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.